Share Price and Basic Stock Data
Last Updated: December 27, 2025, 9:39 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Panacea Biotec Ltd, operating in the pharmaceuticals sector, reported a market capitalization of ₹2,494 Cr with a current share price of ₹407. The company’s revenue from operations has shown fluctuations in recent quarters, with sales for June 2023 at ₹129.19 Cr, slightly rising to ₹143.02 Cr by September 2023. However, a noticeable decline occurred in March 2024 when sales fell to ₹136.46 Cr. In the subsequent quarter, June 2024, sales further dropped to ₹115.72 Cr, before rebounding to ₹147.35 Cr in September 2024 and reaching ₹163.49 Cr in December 2024. The trailing twelve months (TTM) revenue stood at ₹604 Cr, indicating ongoing revenue challenges compared to previous years when sales were as high as ₹687 Cr in March 2015. This revenue instability underscores a need for strategic measures to stabilize income streams.
Profitability and Efficiency Metrics
Panacea Biotec’s profitability metrics reflect significant challenges. The company reported a negative operating profit margin (OPM) of -0.71%, indicating that operational costs exceed revenue. Quarterly data reveals deepening losses, with net profit reaching a low of -₹12.68 Cr in March 2023 and improving slightly to -₹2.20 Cr by December 2023. The interest coverage ratio stood at -1.36x, highlighting difficulties in meeting interest obligations, which may impact investor confidence. Return on equity (ROE) is at a low of 4.92%, while return on capital employed (ROCE) is marginally lower at 4.57%, both well below industry standards. The cash conversion cycle of 25 days suggests operational efficiency, yet the negative profit margins indicate a pressing need for restructuring to enhance profitability.
Balance Sheet Strength and Financial Ratios
Panacea Biotec’s balance sheet reveals a mixed picture. The company holds reserves of ₹820 Cr against borrowings of ₹23 Cr, suggesting a conservative debt profile. The debt-to-equity ratio is minimal at 0.01x, indicating low leverage, which is a strength in volatile markets. However, the price-to-book value ratio of 3.32x suggests that the stock may be overvalued relative to its book value, which stood at ₹132.76 per share in March 2025. The current ratio of 1.49x indicates adequate short-term liquidity, while the quick ratio of 0.90x raises concerns about immediate cash availability. Overall, while the company maintains a strong reserve position, its profitability and efficiency ratios necessitate immediate attention to improve financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Panacea Biotec indicates a strong promoter presence, holding 72.48% of the shares, which may assure investors of stability and control. Foreign institutional investors (FIIs) have increased their stake to 1.06%, while domestic institutional investors (DIIs) hold 1.80%. The public shareholding stands at 24.65%, with a total of 33,593 shareholders as of March 2025. This distribution suggests a relatively low level of institutional investment, which could be a point of concern for future capital raising. The gradual decline in public shareholding from 25.81% in December 2022 to the current level indicates potential waning interest among retail investors. Increased FII participation could signal a shift in market perception, but the overall low institutional presence may limit stock liquidity and price support.
Outlook, Risks, and Final Insight
Looking ahead, Panacea Biotec faces several risks that could impact its operational and financial performance. The ongoing negative profitability trends, highlighted by multiple quarters of net losses, pose a significant risk to investor confidence and future growth. Additionally, the company’s dependence on a limited product portfolio could hinder revenue diversification, making it vulnerable to market fluctuations. However, the strong promoter backing and low debt levels provide a buffer against financial distress. The company’s ability to stabilize revenue and enhance profitability through strategic initiatives will be critical. If Panacea can successfully implement operational improvements and capitalize on growth opportunities in the pharmaceutical sector, it may regain investor confidence and improve its financial standing in the coming quarters. Conversely, continued operational inefficiencies could lead to further declines in market valuation and shareholder sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,830 Cr. | 443 | 479/192 | 100 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,105.46 Cr | 1,149.90 | 52.70 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 110.70 | 105.12 | 115.20 | 128.93 | 129.19 | 143.02 | 150.50 | 136.46 | 115.72 | 147.35 | 163.49 | 132.53 | 166.70 |
| Expenses | 190.51 | 108.96 | 123.84 | 134.60 | 139.50 | 146.58 | 150.65 | 142.50 | 129.71 | 140.35 | 155.53 | 159.41 | 167.88 |
| Operating Profit | -79.81 | -3.84 | -8.64 | -5.67 | -10.31 | -3.56 | -0.15 | -6.04 | -13.99 | 7.00 | 7.96 | -26.88 | -1.18 |
| OPM % | -72.10% | -3.65% | -7.50% | -4.40% | -7.98% | -2.49% | -0.10% | -4.43% | -12.09% | 4.75% | 4.87% | -20.28% | -0.71% |
| Other Income | 39.95 | 38.22 | 41.71 | 34.44 | 33.82 | 6.00 | 8.46 | 13.55 | 6.54 | 7.42 | 6.39 | 36.30 | 16.99 |
| Interest | 1.25 | 1.18 | 0.96 | 1.05 | 1.00 | 0.91 | 0.85 | 0.82 | 0.87 | 0.98 | 0.99 | 1.04 | 0.86 |
| Depreciation | 10.05 | 9.89 | 9.67 | 9.51 | 9.48 | 9.31 | 9.11 | 8.81 | 8.73 | 8.68 | 8.98 | 8.42 | 8.39 |
| Profit before tax | -51.16 | 23.31 | 22.44 | 18.21 | 13.03 | -7.78 | -1.65 | -2.12 | -17.05 | 4.76 | 4.38 | -0.04 | 6.56 |
| Tax % | 9.73% | 32.65% | 13.68% | 169.63% | 15.73% | 6.56% | 33.33% | -6.13% | -6.86% | 1.05% | -1.37% | 4,875.00% | 39.63% |
| Net Profit | -56.14 | 15.70 | 19.37 | -12.68 | 10.98 | -8.29 | -2.20 | -1.99 | -15.88 | 4.71 | 4.44 | -1.99 | 3.96 |
| EPS in Rs | -9.16 | 2.56 | 3.16 | -2.07 | 1.79 | -1.35 | -0.37 | -0.32 | -2.58 | 0.78 | 0.74 | -0.31 | 0.66 |
Last Updated: August 20, 2025, 5:45 am
Below is a detailed analysis of the quarterly data for Panacea Biotec Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 166.70 Cr.. The value appears strong and on an upward trend. It has increased from 132.53 Cr. (Mar 2025) to 166.70 Cr., marking an increase of 34.17 Cr..
- For Expenses, as of Jun 2025, the value is 167.88 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 159.41 Cr. (Mar 2025) to 167.88 Cr., marking an increase of 8.47 Cr..
- For Operating Profit, as of Jun 2025, the value is -1.18 Cr.. The value appears strong and on an upward trend. It has increased from -26.88 Cr. (Mar 2025) to -1.18 Cr., marking an increase of 25.70 Cr..
- For OPM %, as of Jun 2025, the value is -0.71%. The value appears strong and on an upward trend. It has increased from -20.28% (Mar 2025) to -0.71%, marking an increase of 19.57%.
- For Other Income, as of Jun 2025, the value is 16.99 Cr.. The value appears to be declining and may need further review. It has decreased from 36.30 Cr. (Mar 2025) to 16.99 Cr., marking a decrease of 19.31 Cr..
- For Interest, as of Jun 2025, the value is 0.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.04 Cr. (Mar 2025) to 0.86 Cr., marking a decrease of 0.18 Cr..
- For Depreciation, as of Jun 2025, the value is 8.39 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.42 Cr. (Mar 2025) to 8.39 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Jun 2025, the value is 6.56 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Mar 2025) to 6.56 Cr., marking an increase of 6.60 Cr..
- For Tax %, as of Jun 2025, the value is 39.63%. The value appears to be improving (decreasing) as expected. It has decreased from 4,875.00% (Mar 2025) to 39.63%, marking a decrease of 4,835.37%.
- For Net Profit, as of Jun 2025, the value is 3.96 Cr.. The value appears strong and on an upward trend. It has increased from -1.99 Cr. (Mar 2025) to 3.96 Cr., marking an increase of 5.95 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.66. The value appears strong and on an upward trend. It has increased from -0.31 (Mar 2025) to 0.66, marking an increase of 0.97.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:51 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 510 | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | 604 |
| Expenses | 582 | 643 | 541 | 505 | 509 | 591 | 490 | 548 | 674 | 558 | 574 | 584 | 642 |
| Operating Profit | -72 | 44 | 112 | 39 | 84 | -134 | 54 | 77 | -13 | -98 | -15 | -25 | -38 |
| OPM % | -14% | 6% | 17% | 7% | 14% | -29% | 10% | 12% | -2% | -21% | -3% | -4% | -6% |
| Other Income | 183 | 28 | 70 | 62 | 8 | 338 | -14 | 9 | 1,687 | 154 | 57 | 55 | 69 |
| Interest | 150 | 105 | 127 | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 | 4 | 5 |
| Depreciation | 71 | 67 | 73 | 68 | 57 | 54 | 43 | 46 | 44 | 39 | 37 | 35 | 34 |
| Profit before tax | -111 | -99 | -19 | -67 | -66 | 45 | -178 | -146 | 1,449 | 13 | 1 | -8 | -8 |
| Tax % | 2% | 3% | 10% | -16% | 15% | 17% | 9% | 1% | 26% | 363% | 201% | 10% | |
| Net Profit | -113 | -108 | -21 | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -2 | -9 | -8 |
| EPS in Rs | -18.29 | -17.38 | -2.98 | -8.89 | -12.07 | 6.15 | -31.69 | -24.09 | 175.91 | -5.42 | -0.19 | -1.37 | -1.18 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 4.42% | 80.56% | -166.67% | -35.71% | 150.00% | -610.53% | 23.71% | 828.38% | -103.15% | 94.12% | -350.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 76.13% | -247.22% | 130.95% | 185.71% | -760.53% | 634.24% | 804.67% | -931.53% | 197.27% | -444.12% |
Panacea Biotec Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 1% |
| 3 Years: | -5% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 21% |
| TTM: | 29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 19% |
| 3 Years: | 43% |
| 1 Year: | 71% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| Last Year: | -5% |
Last Updated: September 5, 2025, 12:05 pm
Balance Sheet
Last Updated: December 4, 2025, 1:46 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 507 | 449 | 426 | 350 | 303 | 344 | 193 | -235 | 871 | 837 | 836 | 829 | 820 |
| Borrowings | 1,060 | 1,111 | 1,105 | 994 | 941 | 646 | 742 | 820 | 34 | 20 | 21 | 22 | 23 |
| Other Liabilities | 371 | 364 | 317 | 440 | 349 | 379 | 449 | 587 | 848 | 407 | 378 | 433 | 405 |
| Total Liabilities | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 | 1,254 |
| Fixed Assets | 1,276 | 1,144 | 1,071 | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 582 | 567 | 594 |
| CWIP | 172 | 155 | 161 | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 102 | 128 | 110 |
| Investments | 16 | 15 | 9 | 7 | 7 | 5 | 6 | 0 | 5 | 13 | 40 | 3 | 3 |
| Other Assets | 479 | 616 | 614 | 750 | 602 | 542 | 703 | 534 | 1,114 | 615 | 517 | 592 | 547 |
| Total Assets | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 | 1,254 |
Below is a detailed analysis of the balance sheet data for Panacea Biotec Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Reserves, as of Sep 2025, the value is 820.00 Cr.. The value appears to be declining and may need further review. It has decreased from 829.00 Cr. (Mar 2025) to 820.00 Cr., marking a decrease of 9.00 Cr..
- For Borrowings, as of Sep 2025, the value is 23.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 22.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 405.00 Cr.. The value appears to be improving (decreasing). It has decreased from 433.00 Cr. (Mar 2025) to 405.00 Cr., marking a decrease of 28.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,254.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,290.00 Cr. (Mar 2025) to 1,254.00 Cr., marking a decrease of 36.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 594.00 Cr.. The value appears strong and on an upward trend. It has increased from 567.00 Cr. (Mar 2025) to 594.00 Cr., marking an increase of 27.00 Cr..
- For CWIP, as of Sep 2025, the value is 110.00 Cr.. The value appears to be declining and may need further review. It has decreased from 128.00 Cr. (Mar 2025) to 110.00 Cr., marking a decrease of 18.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 547.00 Cr.. The value appears to be declining and may need further review. It has decreased from 592.00 Cr. (Mar 2025) to 547.00 Cr., marking a decrease of 45.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,254.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,290.00 Cr. (Mar 2025) to 1,254.00 Cr., marking a decrease of 36.00 Cr..
Notably, the Reserves (820.00 Cr.) exceed the Borrowings (23.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -73.00 | 43.00 | 111.00 | -955.00 | -857.00 | -780.00 | -688.00 | -743.00 | -47.00 | -118.00 | -36.00 | -47.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 52 | 79 | 95 | 84 | 71 | 46 | 49 | 45 | 48 | 37 | 47 |
| Inventory Days | 375 | 404 | 516 | 770 | 651 | 173 | 344 | 311 | 296 | 292 | 282 | 391 |
| Days Payable | 430 | 272 | 318 | 607 | 540 | 572 | 463 | 440 | 327 | 256 | 244 | 413 |
| Cash Conversion Cycle | 13 | 184 | 278 | 259 | 195 | -328 | -73 | -80 | 14 | 83 | 76 | 25 |
| Working Capital Days | -343 | -126 | 27 | -46 | -96 | -363 | 95 | -43 | -229 | -5 | -2 | 46 |
| ROCE % | -8% | 0% | 4% | 2% | 3% | -16% | 4% | 5% | -6% | -10% | -4% | -5% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 117 | 0.02 | 0 | 117 | 2025-04-22 17:25:23 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| Diluted EPS (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| Cash EPS (Rs.) | 4.26 | 5.75 | 0.87 | 183.11 | -16.68 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 132.76 | 133.94 | 133.63 | 138.09 | -41.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 132.76 | 133.94 | 133.63 | 138.09 | -41.36 |
| Revenue From Operations / Share (Rs.) | 91.28 | 91.29 | 75.09 | 107.96 | 102.01 |
| PBDIT / Share (Rs.) | -0.85 | 0.93 | -7.56 | -0.47 | 14.14 |
| PBIT / Share (Rs.) | -6.54 | -5.06 | -13.95 | -7.60 | 6.70 |
| PBT / Share (Rs.) | -1.30 | 0.24 | 2.09 | 236.54 | -23.56 |
| Net Profit / Share (Rs.) | -1.42 | -0.24 | -5.51 | 175.98 | -24.12 |
| NP After MI And SOA / Share (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| PBDIT Margin (%) | -0.93 | 1.02 | -10.06 | -0.43 | 13.86 |
| PBIT Margin (%) | -7.16 | -5.53 | -18.57 | -7.04 | 6.56 |
| PBT Margin (%) | -1.42 | 0.26 | 2.78 | 219.10 | -23.09 |
| Net Profit Margin (%) | -1.55 | -0.26 | -7.33 | 163.01 | -23.64 |
| NP After MI And SOA Margin (%) | -1.49 | -0.20 | -7.22 | 163.01 | -23.63 |
| Return on Networth / Equity (%) | -1.02 | -0.14 | -4.04 | 126.99 | 0.00 |
| Return on Capital Employeed (%) | -4.34 | -3.32 | -9.09 | -4.75 | 5.44 |
| Return On Assets (%) | -0.64 | -0.09 | -2.61 | 60.47 | -12.52 |
| Long Term Debt / Equity (X) | 0.01 | 0.01 | 0.01 | 0.03 | -2.92 |
| Total Debt / Equity (X) | 0.01 | 0.01 | 0.01 | 0.03 | -2.92 |
| Asset Turnover Ratio (%) | 0.44 | 0.44 | 0.30 | 0.24 | 0.31 |
| Current Ratio (X) | 1.49 | 1.57 | 1.71 | 1.30 | 1.20 |
| Quick Ratio (X) | 0.90 | 0.99 | 1.10 | 1.03 | 0.79 |
| Inventory Turnover Ratio (X) | 2.86 | 1.11 | 1.02 | 1.14 | 0.58 |
| Interest Coverage Ratio (X) | -1.36 | 1.60 | -10.43 | -0.01 | 0.46 |
| Interest Coverage Ratio (Post Tax) (X) | -10.54 | -9.48 | -29.74 | -2.31 | 0.21 |
| Enterprise Value (Cr.) | 2610.05 | 620.65 | 454.38 | 355.93 | 1682.86 |
| EV / Net Operating Revenue (X) | 4.67 | 1.11 | 0.98 | 0.53 | 2.69 |
| EV / EBITDA (X) | -496.96 | 108.22 | -9.81 | -122.86 | 19.43 |
| MarketCap / Net Operating Revenue (X) | 4.83 | 1.33 | 1.44 | 1.37 | 1.74 |
| Price / BV (X) | 3.32 | 0.90 | 0.80 | 1.07 | -4.34 |
| Price / Net Operating Revenue (X) | 4.83 | 1.33 | 1.44 | 1.37 | 1.74 |
| EarningsYield | 0.00 | 0.00 | -0.05 | 1.19 | -0.13 |
After reviewing the key financial ratios for Panacea Biotec Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 5. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For Diluted EPS (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 5. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.26. This value is within the healthy range. It has decreased from 5.75 (Mar 24) to 4.26, marking a decrease of 1.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 132.76. It has decreased from 133.94 (Mar 24) to 132.76, marking a decrease of 1.18.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 132.76. It has decreased from 133.94 (Mar 24) to 132.76, marking a decrease of 1.18.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 91.28. It has decreased from 91.29 (Mar 24) to 91.28, marking a decrease of 0.01.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.85. This value is below the healthy minimum of 2. It has decreased from 0.93 (Mar 24) to -0.85, marking a decrease of 1.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is -6.54. This value is below the healthy minimum of 0. It has decreased from -5.06 (Mar 24) to -6.54, marking a decrease of 1.48.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.30. This value is below the healthy minimum of 0. It has decreased from 0.24 (Mar 24) to -1.30, marking a decrease of 1.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 2. It has decreased from -0.24 (Mar 24) to -1.42, marking a decrease of 1.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 2. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For PBDIT Margin (%), as of Mar 25, the value is -0.93. This value is below the healthy minimum of 10. It has decreased from 1.02 (Mar 24) to -0.93, marking a decrease of 1.95.
- For PBIT Margin (%), as of Mar 25, the value is -7.16. This value is below the healthy minimum of 10. It has decreased from -5.53 (Mar 24) to -7.16, marking a decrease of 1.63.
- For PBT Margin (%), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 10. It has decreased from 0.26 (Mar 24) to -1.42, marking a decrease of 1.68.
- For Net Profit Margin (%), as of Mar 25, the value is -1.55. This value is below the healthy minimum of 5. It has decreased from -0.26 (Mar 24) to -1.55, marking a decrease of 1.29.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.49. This value is below the healthy minimum of 8. It has decreased from -0.20 (Mar 24) to -1.49, marking a decrease of 1.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.02. This value is below the healthy minimum of 15. It has decreased from -0.14 (Mar 24) to -1.02, marking a decrease of 0.88.
- For Return on Capital Employeed (%), as of Mar 25, the value is -4.34. This value is below the healthy minimum of 10. It has decreased from -3.32 (Mar 24) to -4.34, marking a decrease of 1.02.
- For Return On Assets (%), as of Mar 25, the value is -0.64. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -0.64, marking a decrease of 0.55.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. There is no change compared to the previous period (Mar 24) which recorded 0.44.
- For Current Ratio (X), as of Mar 25, the value is 1.49. This value is below the healthy minimum of 1.5. It has decreased from 1.57 (Mar 24) to 1.49, marking a decrease of 0.08.
- For Quick Ratio (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.90, marking a decrease of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 4. It has increased from 1.11 (Mar 24) to 2.86, marking an increase of 1.75.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.36. This value is below the healthy minimum of 3. It has decreased from 1.60 (Mar 24) to -1.36, marking a decrease of 2.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -10.54. This value is below the healthy minimum of 3. It has decreased from -9.48 (Mar 24) to -10.54, marking a decrease of 1.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,610.05. It has increased from 620.65 (Mar 24) to 2,610.05, marking an increase of 1,989.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.67. This value exceeds the healthy maximum of 3. It has increased from 1.11 (Mar 24) to 4.67, marking an increase of 3.56.
- For EV / EBITDA (X), as of Mar 25, the value is -496.96. This value is below the healthy minimum of 5. It has decreased from 108.22 (Mar 24) to -496.96, marking a decrease of 605.18.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.83. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.83, marking an increase of 3.50.
- For Price / BV (X), as of Mar 25, the value is 3.32. This value exceeds the healthy maximum of 3. It has increased from 0.90 (Mar 24) to 3.32, marking an increase of 2.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.83. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.83, marking an increase of 3.50.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Panacea Biotec Ltd:
- Net Profit Margin: -1.55%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -4.34% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.02% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -10.54
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.9
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.7)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -1.55%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Ambala-Chandigarh Highway, Lalru Punjab 140501 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Rajesh Jain | Chairman & Managing Director |
| Mr. Sandeep Jain | Joint Managing Director |
| Mr. Ankesh Jain | Whole Time Director |
| Mr. Harshet Jain | Whole Time Director |
| Mr. Mukul Gupta | Independent Director |
| Mrs. Ambika Sharma | Independent Director |
| Dr. Sanjay Trehan | Director - Technical |
| Mr. Krishan Kumar Jalan | Independent Director |
| Dr. Rajender Pal Singh | Independent Director |
| Dr. Venkatesh Sarvasiddhi | Independent Director |
| CA. Rajesh Jain. | Independent Director |
FAQ
What is the intrinsic value of Panacea Biotec Ltd?
Panacea Biotec Ltd's intrinsic value (as of 27 December 2025) is 81.30 which is 80.02% lower the current market price of 407.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,494 Cr. market cap, FY2025-2026 high/low of 582/281, reserves of ₹820 Cr, and liabilities of 1,254 Cr.
What is the Market Cap of Panacea Biotec Ltd?
The Market Cap of Panacea Biotec Ltd is 2,494 Cr..
What is the current Stock Price of Panacea Biotec Ltd as on 27 December 2025?
The current stock price of Panacea Biotec Ltd as on 27 December 2025 is 407.
What is the High / Low of Panacea Biotec Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Panacea Biotec Ltd stocks is 582/281.
What is the Stock P/E of Panacea Biotec Ltd?
The Stock P/E of Panacea Biotec Ltd is .
What is the Book Value of Panacea Biotec Ltd?
The Book Value of Panacea Biotec Ltd is 135.
What is the Dividend Yield of Panacea Biotec Ltd?
The Dividend Yield of Panacea Biotec Ltd is 0.00 %.
What is the ROCE of Panacea Biotec Ltd?
The ROCE of Panacea Biotec Ltd is 4.57 %.
What is the ROE of Panacea Biotec Ltd?
The ROE of Panacea Biotec Ltd is 4.92 %.
What is the Face Value of Panacea Biotec Ltd?
The Face Value of Panacea Biotec Ltd is 1.00.